Loading...
•
Jun 30, 2024
Alector Q2 2024 Earnings Report
Alector's progress in clinical trials and strong financial position were highlighted.
Key Takeaways
Alector reported a net loss of $38.7 million for Q2 2024, with collaboration revenue of $15.1 million. The company's cash, cash equivalents, and investments totaled $503.3 million, expected to fund operations through 2026. Key clinical trials for AL002 and latozinemab are progressing, with potential data readouts and regulatory interactions anticipated.
INVOKE-2 Phase 2 clinical trial data for AL002 in early Alzheimer’s disease is expected in Q4 2024.
The pivotal INFRONT-3 Phase 3 trial of latozinemab continues to progress well, supported by FDA interaction post Breakthrough Therapy Designation.
Alector's cash, cash equivalents, and investments totaled $503.3 million, providing runway through 2026.
Alector is advancing its Alector Brain Carrier (ABC) technology for delivering drugs into the CNS.
Forward Guidance
Alector anticipates collaboration revenue between $60 million and $70 million. Total research and development expenses are expected to be between $210 million and $220 million, and total general and administrative expenses are projected to be between $60 million and $70 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...